Health Care · Biological Products, (No Diagnostic Substances)

EDIT Editas Medicine, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1650664101 filings
Russell 2000

EDIT at a glance

Editas Medicine, Inc. (EDIT, SEC CIK 1650664) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Editas Medicine, Inc. (EDIT) reported revenue of $40.5 million (up 25.4% from FY2024) and a net loss of $160.1 million. Diluted EPS was -$1.80.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Editas Medicine, Inc. (EDIT) shares worth $132.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by O'Neill Gilmore Neil on November 11, 2026 of 21,164 shares at $2.42 per share.
  • In the last 90 days, EDIT insiders reported 0 open-market purchases ($0) and 5 open-market sales ($89K) on Form 4, a net sale of $89K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$40.5M
+25.4% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$89K
13F holders
28 funds
$132.3M · +2 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $10.4M, up $2.8M from $7.5M YoY, driven by strategic-partner clinical milestones
  • Net loss $23.4M vs $25.1M YoY, with operating expenses $34.6M vs $32.1M
  • Research and development $21.2M, up $1.4M YoY, driven by $3.6M higher sublicense and license fees
  • Cash, equivalents, and marketable securities $190.2M; operating cash outflow $73.8M through nine months
  • EDIT-401 dosing on track for 2026; initial safety data expected first quarter 2027, cash runway into second half of 2028

Risk Factors

  • No updated Risk Factors text provided, so no newly added quarterly risk identified
  • Liquidity risk: accumulated deficit $1.7 billion and substantial additional capital required despite $190.2 million in cash, equivalents, and marketable securities
  • Regulatory and legal risk: Cas9-I patent license disputes require $10.8 million reimbursement payments year-to-date
  • Operational risk: gene-editing programs depend on successful clinical development, regulatory approval, manufacturing, and commercialization
  • Financial risk: DRI revenue-sale liability $56.8 million, with estimated effective interest rate 7.7%

AI summary of the EDIT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Editas Medicine reported financial results for the quarter ended September 30, 2026
  • Business highlights accompany the quarterly results in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Phase 1/2 Strive study approved in Australia, with EDIT-401 dosing expected in 2026 and initial safety data targeted for Q1 2027
  • EDIT-401 preclinical LDL-C reduction of ≥90% maintained over 10 months, supporting potential durability but not yet demonstrating human efficacy
Filed Oct 8, 2026Full analysis →

Item 8.01: Other Events

  • Australia approval enables Phase 1/2 Strive trial of EDIT-401 in heterozygous familial hypercholesterolemia
  • EDIT-401 targets LDLR upregulation, with approximately 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates

Item 7.01: Regulation FD Disclosure

  • FDA approval to initiate first-in-human EDIT-401 trial in hyperlipidemia
  • Clinical-stage milestone enabling initial human safety and efficacy testing
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Editas Medicine’s quarter ended June 30, 2026 financial results
  • Exhibit 99.1 contains business highlights and detailed quarterly results

Item EX-99.1: Item EX-99.1

  • EDIT-401 CTN submission targeted for August 2026, with Phase 1/2 data update expected in Q1 2027
  • Preclinical EDIT-401 data showed approximately 90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Elliott Levy resigned as class I director effective August 4, 2026, without disagreement with Editas Medicine
  • Patrick Ellinor appointed independent class I director effective August 6, 2026

AI summaries of EDIT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EDIT

Don't miss the next EDIT filing

  • Alerts as it files. A push when EDIT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EDIT, by share count.
  • Ask anything. An AI agent that reads every EDIT filing and answers with sources.

EDIT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
O'Neill Gilmore NeilSellNov 11, 2026$2.42
Burkly LindaSellNov 11, 2026$2.42
Burkly LindaANov 5, 2026-
O'Neill Gilmore NeilANov 5, 2026-
Ory Daniel ScottASep 8, 2026-
Parison AmySellSep 3, 2026$3.04
Burkly LindaSellSep 3, 2026$3.04
O'Neill Gilmore NeilSellSep 3, 2026$3.04

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$32.3M$40.5M
Operating Income--$251.2M-$160.0M
Net Income-$153.2M-$237.1M-$160.1M
Op. Margin--777.2%-394.9%
Net Margin--733.7%-395.0%
Balance Sheet
Total Assets$499.2M$341.6M$186.5M
Equity-$134.3M$27.3M
ROE--176.6%-586.6%
Per Share
EPS$-2.02$-2.88$-1.80
Cash Flow
Operating CF--$210.3M-$165.2M
CapEx$4.7M$8.8M$607K

Source: XBRL data in Editas Medicine, Inc. (EDIT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EDIT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EDIT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$132.3M
Q2 202626$125.1M
Q1 202626$84.2M
Q4 202526$67.0M
Q3 202526$98.1M
Q2 202526$62.5M
Q1 202523$26.0M
Q4 202420$26.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EDIT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
4Nov 13, 2026--
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Nov 6, 2026--
4Nov 6, 2026--
8-KOct 8, 2026Analysis-
4Sep 9, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
SC 13GAug 14, 2026-
4Aug 7, 2026--
4Aug 5, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 29, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 18, 2026Analysis-
4Jun 5, 2026-
4Jun 5, 2026-

Related Health Care companies

All Health Care →

EDIT SEC filings: frequently asked questions

Are EDIT insiders buying or selling?

In the last 90 days, Editas Medicine, Inc. (EDIT) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $89,088 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold EDIT stock?

As of September 30, 2026, the largest Editas Medicine, Inc. (EDIT) holders among the 13F filers tracked by SignalX were BlackRock ($37.0 million), State Street Corp ($18.1 million), Vanguard Capital Management LLC ($15.6 million), Vanguard Portfolio Management LLC ($12.0 million), Goldman Sachs Group ($8.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EDIT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Editas Medicine, Inc. (EDIT) reported revenue of $40.5 million (up 25.4% from FY2024) and a net loss of $160.1 million. Diluted EPS was -$1.80. The figures come from the XBRL data in the 10-K.

What did EDIT report in its latest 8-K?

Editas Medicine, Inc. (EDIT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Editas Medicine reported financial results for the quarter ended September 30, 2026.

What are the latest EDIT SEC filings?

Editas Medicine, Inc. (EDIT) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 13, 2026.

What is EDIT's SEC CIK number?

Editas Medicine, Inc. (EDIT)'s SEC Central Index Key (CIK) is 1650664. EDGAR lists every EDIT filing under that number.

Ask anything about EDIT

The research agent reads EDIT's filings, financials, insider trades and 13F holders, then answers with sources.